Skip header and navigation

Refine By

2 records – page 1 of 1.

Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria.

https://arctichealth.org/en/permalink/ahliterature273146
Source
Br J Surg. 2016 Feb;103(3):226-32
Publication Type
Article
Date
Feb-2016
Author
O M Sandvik
K. Søreide
E. Gudlaugsson
J T Kvaløy
J A Søreide
Source
Br J Surg. 2016 Feb;103(3):226-32
Date
Feb-2016
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Distribution
Aged
Aged, 80 and over
Child
Female
Gastrointestinal Neoplasms - classification - epidemiology
Humans
Incidence
Male
Middle Aged
Neoplasm Staging
Neuroendocrine Tumors - classification - epidemiology
Norway - epidemiology
Prevalence
Retrospective Studies
Sex Distribution
World Health Organization
Young Adult
Abstract
The lack of uniform criteria for coding of gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) has hampered previous epidemiological studies. The epidemiology of GEP-NEN was investigated in this study using currently available criteria.
All patients diagnosed with GEP-NEN between January 2003 and December 2013 in a well defined Norwegian population of approximately 350 000 people were included. Age- and sex-adjusted incidence rates were calculated. The current 2010 World Health Organization criteria, European Neuroendocrine Tumour Society classification and International Union Against Cancer (UICC) classification were used.
A total of 204 patients (114 male, 55.9 per cent) were identified. The median age at diagnosis was 61 (range 10-94) years. The annual overall crude incidence was 5.83 per 100,000 inhabitants, with an increasing trend (P = 0.033). The most frequent location was small intestine (60 patients, 29.4 per cent) followed by appendix (48 patients, 23.5 per cent) and pancreas (33 patients, 16.2 per cent). Grade 1 tumours were more common in gastrointestinal (100 patients, 58.5 per cent) than in pancreatic (9 patients, 27 per cent) NEN. According to the UICC classification, 77 patients (37.7 per cent) had stage I, 17 patients (8.3 per cent) stage II, 37 patients (18.1 per cent) stage III and 70 patients (34.3 per cent) had stage IV disease. No patient with stage I disease had grade 3 tumours; advanced tumour grade increased with stage.
A high crude incidence of GEP-NEN, at 5.83 per 100,000 inhabitants, was noted together with a significant increasing trend over time.
PubMed ID
26511392 View in PubMed
Less detail

Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010.

https://arctichealth.org/en/permalink/ahliterature282266
Source
Neuroendocrinology. 2017;104(1):1-10
Publication Type
Article
Date
2017
Author
Raziye Boyar Cetinkaya
Bjarte Aagnes
Espen Thiis-Evensen
Steinar Tretli
Deidi S Bergestuen
Svein Hansen
Source
Neuroendocrinology. 2017;104(1):1-10
Date
2017
Language
English
Publication Type
Article
Keywords
Aged
Female
Humans
Incidence
Longitudinal Studies
Male
Middle Aged
Neuroendocrine Tumors - classification - diagnosis - epidemiology
Norway - epidemiology
Prevalence
Retrospective Studies
Abstract
Epidemiological studies show an increasing trend in the incidence of neuroendocrine neoplasms (NENs). A significant number of NENs occur in less common primary sites, but they are often excluded from the population-based studies. We studied the incidence trends of all NENs in Norway according to different primary sites.
Our analyses were based on cancer cases diagnosed between 1993 and 2010 and reported to the national population-based Cancer Registry of Norway. A total of 65 morphological codes were identified as neuroendocrine and stratified into 3 different groups of aggressiveness: low, intermediate and high.
We identified 16,075 NENs of which 49.5% were in women. The median age at diagnosis was 65 years. The most common primary sites were the lung (48.1%) and the gastroenteropancreatic system (18.0%). Stage at diagnosis was local in 40.4% of the cases, regional in 17.5% and distant in 42.1%. The stage distribution was stable throughout the study period. The age-standardized (European) incidence rate (per 100,000 person-years) increased from 13.3 in 1993 to 21.3 in 2010 with an estimated annual increase of 5.1% in women and 2.1% in men. The increase was most pronounced for tumors of intermediate aggressiveness from 3.3 in 1993 to 7.3 in 2010. The largest annual increases were estimated for the adrenal gland (8.8%), the pancreas (6.9%) and the lungs (6.1%).
The incidence of NENs increased. Most primary tumors were found in the lungs or in the gastroenteropancreatic system. The increase in the incidence differed according to the primary site, gender and tumor aggressiveness.
PubMed ID
26562558 View in PubMed
Less detail